GLP-1 Medications and Kidney Disease: FLOW Trial Evidence

Key Takeaways

• The FLOW trial (Perkovic et al. NEJM 2024) showed semaglutide 1.0 mg weekly reduced major kidney disease events and death by 24% in patients with type 2 diabetes and chronic kidney disease
• The FDA expanded Ozempic's label in 2025 to include renal risk reduction in adults with type 2 diabetes and CKD
• FLOW was stopped early for efficacy at interim analysis
• Non-diabetic CKD is not part of the approved indication; dedicated trials are needed
• Combination with SGLT2 inhibitors is increasingly common in high-risk diabetic CKD

Direct answer

Semaglutide is the first GLP-1 medication with FDA approval for kidney disease risk reduction in patients with type 2 diabetes and chronic kidney disease, granted in 2025 after the FLOW trial reported a 24% reduction in major kidney and cardiovascular events. The mechanism is multifactorial: improved glycemic control, weight loss, blood pressure reduction, and direct anti-inflammatory effects on the kidney. The indication applies specifically to type 2 diabetes; non-diabetic CKD is plausible but not yet proven. Combination with SGLT2 inhibitors is increasingly standard for high-risk patients. Patients on dialysis are excluded from the indication.

Table of contents

1. The diabetic kidney disease problem
2. FLOW trial design and outcomes
3. The early stop for efficacy
4. FDA label expansion in 2025
5. The five proposed mechanisms
6. GLP-1 versus SGLT2 inhibitor: not really an either/or
7. Non-diabetic CKD: the open question
8. Advanced CKD, dialysis, and transplant patients
9. Drug dosing in reduced kidney function
10. Coverage implications
11. Decision framework
12. FAQ
13. Sources

The diabetic kidney disease problem

Diabetic kidney disease (DKD) is among the leading causes of chronic kidney disease and kidney failure globally. Approximately 30-40% of patients with type 2 diabetes develop some degree of kidney involvement. Once established, DKD progresses through stages defined by glomerular filtration rate (GFR) and albuminuria.

Standard DKD treatment before the GLP-1 and SGLT2 era:

• Glycemic control (HbA1c targets)
• Blood pressure control (often with ACE inhibitor or ARB)
• RAAS blockade for proteinuria
• Cardiovascular risk management
• Dietary management (protein restriction, sodium, potassium as appropriate)

These remained foundational but produced incomplete protection. Patients on optimized standard care continued to progress to dialysis or kidney transplantation at meaningful rates.

SGLT2 inhibitors (CREDENCE 2019, DAPA-CKD 2020, EMPA-KIDNEY 2022) established kidney protection beyond standard care, first in diabetic CKD and then in non-diabetic CKD. The question for GLP-1 was whether they could add benefit on top of standard care plus SGLT2 inhibitors.

FLOW trial design and outcomes

FLOW (Effect of Semaglutide vs Placebo on Major Adverse Renal Events in Patients With Type 2 Diabetes and Chronic Kidney Disease) was the dedicated kidney outcome trial of semaglutide. Perkovic et al. published in NEJM 2024.

Design summary:

• 3,533 patients with type 2 diabetes and chronic kidney disease
• CKD inclusion: eGFR 50-75 with UACR 300-5000 mg/g, OR eGFR 25-50 with UACR 100-5000 mg/g
• Semaglutide 1.0 mg weekly versus placebo
• Median follow-up: ~3.4 years
• Primary composite endpoint: kidney failure (initiation of chronic dialysis or kidney transplantation), sustained eGFR decline of ≥50%, kidney-related death, or cardiovascular death

Approximate results:

Outcome	Semaglutide	Placebo	Effect
Primary composite (major kidney/CV events)	~331 events	~410 events	HR 0.76 (24% reduction)
Kidney failure or sustained ≥50% eGFR decline	~21% reduction	-	HR ~0.79
Cardiovascular death	~29% reduction	-	HR ~0.71
All-cause death	~20% reduction	-	HR ~0.80
eGFR slope (annual decline)	Slower	Faster	Mean difference favoring semaglutide
UACR (urine albumin-creatinine ratio)	Reduced	Less change	Geometric mean ratio favoring semaglutide

Both the kidney-specific outcomes and the cardiovascular outcomes moved in semaglutide's favor with statistical significance. The all-cause mortality benefit is particularly notable; few diabetes drugs produce mortality reduction.

The early stop for efficacy

FLOW was stopped early at interim analysis in October 2023. The Data Monitoring Committee recommended stopping after the prespecified efficacy boundary was crossed. The decision reflected the magnitude of benefit being seen on the primary endpoint.

Early stops for efficacy are interpreted carefully:

• They strengthen the case for benefit (the effect size is large enough to detect at interim)
• They may overestimate effect sizes due to regression to the mean
• They limit long-term follow-up for safety signals
• They typically lead to faster regulatory submission

For FLOW, the early stop accelerated Novo Nordisk's submission for a renal indication. The FDA reviewed the data and expanded the Ozempic label in 2025.

FDA label expansion in 2025

The FDA approved an expanded Ozempic label in 2025 adding kidney indication. The relevant labeling language (paraphrased):

• Reduction of risk of sustained eGFR decline, kidney failure, and cardiovascular death
• In adults with type 2 diabetes mellitus and chronic kidney disease
• Dose: 1.0 mg weekly (the dose used in FLOW)

The label is type 2 diabetes specific. Non-diabetic CKD is not covered by the indication.

Practical implications:

• Ozempic now has three FDA indications: type 2 diabetes glycemic control, cardiovascular risk reduction in T2D with established CVD, and kidney/cardiovascular protection in T2D with CKD
• Wegovy (semaglutide 2.4 mg) does not currently have the kidney indication; the FLOW dose was 1.0 mg
• Other GLP-1 medications (tirzepatide, liraglutide, dulaglutide) do not have FLOW-style kidney outcomes data; their kidney effects are presumed but not formally proven

Dulaglutide had REWIND trial data suggesting kidney benefit; tirzepatide kidney outcome trials are in design but had not reported as of May 2026.

The five proposed mechanisms

How GLP-1 protects the kidney is multifactorial:

Mechanism 1: Improved glycemic control. Hyperglycemia drives glomerular damage through multiple pathways (advanced glycation end products, oxidative stress, inflammation). Lower HbA1c reduces this driving force.

Mechanism 2: Weight loss. Obesity contributes to hyperfiltration and glomerular stress. Weight reduction lowers metabolic load on the kidney.

Mechanism 3: Blood pressure reduction. GLP-1 medications produce modest blood pressure decreases (~2-5 mmHg systolic). In CKD, this contributes to slowing decline.

Mechanism 4: Direct anti-inflammatory effects. GLP-1 receptors are present in kidney tissue. Receptor activation reduces inflammatory markers and may slow tubular and interstitial damage independent of metabolic effects.

Mechanism 5: Cardiovascular protection. Heart and kidney are tightly coupled (cardiorenal axis). Reducing heart failure events, MI, and other CV events reduces secondary kidney damage from hemodynamic instability.

The clinical effect (eGFR slope, hard endpoints) is the aggregate of all five. Mechanistic dissection is interesting but not necessary for treatment decisions.

GLP-1 versus SGLT2 inhibitor: not really an either/or

The two drug classes are increasingly used together in high-risk diabetic CKD. Mechanisms are non-overlapping.

Feature	GLP-1 (semaglutide)	SGLT2 inhibitor (empagliflozin, dapagliflozin)
Glycemic effect	Strong	Moderate
Weight loss	Substantial	Modest
Blood pressure	Modest reduction	Modest reduction
Cardiovascular protection	Established (SELECT, FLOW, others)	Established (EMPA-REG, DECLARE-TIMI, others)
Kidney protection in diabetic CKD	Established (FLOW)	Established (CREDENCE)
Kidney protection in non-diabetic CKD	Not established	Established (DAPA-CKD, EMPA-KIDNEY)
Heart failure protection	Limited direct data	Strong direct data
Major side effects	GI	Genital infections, euglycemic DKA

Current consensus among nephrology and endocrinology guidelines is that high-risk diabetic CKD patients benefit from both medications. The combination is associated with additional event reduction beyond either alone in observational analyses.

For patients without diabetes, SGLT2 inhibitors have stronger evidence than GLP-1 in CKD protection.

Non-diabetic CKD: the open question

FLOW enrolled only patients with type 2 diabetes. Whether GLP-1 medications protect non-diabetic CKD is uncertain.

The case for plausible benefit:

• Many mechanisms (weight loss, blood pressure, inflammation) are not diabetes-specific
• Obesity-related kidney disease is common in non-diabetic CKD
• Cardiovascular benefits (SELECT trial) are independent of diabetes

The case for uncertainty:

• FLOW did not enroll non-diabetic patients
• Hyperglycemia is a major driver in DKD that is absent in many non-diabetic CKD cases
• The optimal dose for non-diabetic CKD may differ from the 1.0 mg used in FLOW

Dedicated trials in non-diabetic CKD are in design. The 2026-2029 readout window may clarify whether the renal indication can extend beyond diabetes.

Advanced CKD, dialysis, and transplant patients

FLOW excluded patients on dialysis. The approved indication applies to CKD patients who have not progressed to kidney failure.

For patients on dialysis:

• Semaglutide is not recommended for renal protection; that benefit applies to slowing progression, not reversing established kidney failure
• Semaglutide may still be used for diabetes management or obesity in dialysis patients, with adjusted monitoring
• Cardiovascular and metabolic management continue under nephrology direction

For kidney transplant patients:

• Specific GLP-1 data in this population are limited
• Drug-drug interactions with immunosuppressants are not problematic for the most part
• Weight management post-transplant is important; GLP-1 may be useful
• Coordination with transplant nephrology is essential

Drug dosing in reduced kidney function

Semaglutide does not require dose adjustment for reduced kidney function. The drug is metabolized through proteolytic degradation rather than renal excretion of intact drug.

Other GLP-1 medications:

• Liraglutide: no dose adjustment needed; use with caution in severe renal impairment
• Dulaglutide: no dose adjustment; some caution in severe renal impairment
• Tirzepatide: no dose adjustment; limited data in severe renal impairment
• Exenatide: avoid in severe renal impairment (eGFR < 30); renally excreted

The lack of dose adjustment for semaglutide and tirzepatide simplifies use in CKD patients.

Coverage implications

The 2025 label expansion created a new coverage path for Ozempic. Patients with type 2 diabetes and CKD now have a third indication to support coverage requests, alongside diabetes itself and CVD-with-T2D.

Practical effects:

• Plans that resisted Ozempic coverage for borderline cases may approve more readily when CKD is documented
• Prior authorization specifically for the kidney indication may be a path when standard diabetes coverage is blocked
• Medicare Part D covers Ozempic for diabetes; the renal indication is within the existing T2D coverage rather than a separate path

Wegovy (semaglutide 2.4 mg, obesity dose) does not carry the kidney indication. Patients seeking the kidney benefit specifically should use Ozempic 1.0 mg, the FLOW dose.

Decision framework

If you have type 2 diabetes and CKD: Discuss Ozempic 1.0 mg with your nephrologist and endocrinologist. Coverage path is established. Combination with SGLT2 inhibitor is often recommended.

If you have type 2 diabetes without CKD: Standard diabetes management; Ozempic for glycemic control and weight management. Kidney protection is a possible secondary benefit.

If you have non-diabetic CKD: Standard CKD management. SGLT2 inhibitors have stronger evidence than GLP-1 in this population. Discuss with nephrology; some clinicians use GLP-1 if obesity is significant.

If you have advanced CKD approaching dialysis: Nephrology guidance is essential. Some medications change at this stage; coordination of care is key.

If you are on dialysis: GLP-1 for renal protection is not indicated. Other indications may apply. Coordinate with nephrology.

If you are a kidney transplant recipient: Discuss with your transplant team. Most GLP-1 medications are compatible with immunosuppression.

Compounded medication note for this topic

For GLP-1 Medications and Kidney Disease: FLOW Trial Evidence, keep the pharmacy distinction clear: when compounded semaglutide or tirzepatide is prescribed, it is prepared for an individual patient by a licensed 503A compounding pharmacy. Compounded preparations are not FDA-approved drug products and are not interchangeable with Ozempic, Wegovy, Mounjaro, or Zepbound.

The practical question is not whether a compounded medication is a brand substitute. It is whether the prescription, pharmacy label, concentration, follow-up plan, and adverse-event support are clear enough for your specific medical history.

FAQ

Do GLP-1 medications help kidney disease?

Yes, in diabetic CKD. FLOW showed 24% reduction in major kidney and cardiovascular events.

What did FLOW show?

Semaglutide 1.0 mg weekly reduced kidney failure, eGFR decline, and CV death by 24% in T2D plus CKD. Trial stopped early for efficacy.

Is Ozempic FDA-approved for kidney disease?

Yes, since 2025, for type 2 diabetes with CKD. Non-diabetic CKD is not part of the approval.

Does it work for non-diabetic CKD?

Not established. Plausible but unproven. SGLT2 inhibitors have stronger evidence in non-diabetic CKD.

How does GLP-1 protect the kidney?

Multiple mechanisms: glycemic control, weight loss, blood pressure, direct anti-inflammatory effects, cardiovascular protection.

Should I take Ozempic with an SGLT2 inhibitor?

Often yes in diabetic CKD. Non-overlapping mechanisms; combination is increasingly standard.

What if I'm on dialysis?

Semaglutide is not indicated for renal protection at dialysis stage. Cardiovascular and diabetes management continue under nephrology.

Does the kidney indication change insurance coverage?

Yes, in expansion. CKD provides an additional coverage path for Ozempic.

What dose is used for kidney protection?

Ozempic 1.0 mg weekly. This is the FLOW dose. The 2.4 mg Wegovy dose does not carry the kidney indication.

Does tirzepatide help the kidney?

Likely yes based on mechanism, but no FLOW-equivalent trial has reported. Phase 3 kidney outcome trial in design.

Do I need a nephrologist?

For CKD management generally, yes. Coordinated care between nephrology and the GLP-1 prescriber is preferable.

What about kidney stones?

GLP-1 medications do not have a clear association with kidney stones. Some debate exists about dehydration during severe GI symptoms; staying hydrated is sensible.

Related guides

• Why GLP-1 Medications Create a Perfect Storm for Both Kidney Stones and Constipation (and the Prevention Protocol That Addresses Both)
• Has Anyone Gotten Cancer from Ozempic? The Clinical Evidence on GLP-1 Medications and Cancer Risk
• GLP-1 Medications for PCOS: What the Evidence Actually Shows
• GLP-1 Medications for MASH and Fatty Liver: The Evidence Map
• GLP-1 Medications for Sleep Apnea: The SURMOUNT-OSA Evidence
• GLP-1 Medications and Alcohol Use Disorder: The Emerging Evidence

Sources

1. Perkovic V et al. Effects of Semaglutide on Chronic Kidney Disease in Patients With Type 2 Diabetes (FLOW). New England Journal of Medicine. 2024.
2. FDA Drug Label. Ozempic (semaglutide) Prescribing Information. Updated 2025 to include CKD indication.
3. Perkovic V et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy (CREDENCE). NEJM. 2019.
4. Heerspink HJL et al. Dapagliflozin in Patients with Chronic Kidney Disease (DAPA-CKD). NEJM. 2020.
5. The EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. NEJM. 2022.
6. KDIGO. Clinical Practice Guideline for Diabetes Management in CKD. 2022.
7. American Diabetes Association. Standards of Care in Diabetes. 2026.
8. Endocrine Society. Clinical Practice Guideline on Diabetic Kidney Disease. 2024 update.
9. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT). NEJM. 2023.
10. Gerstein HC et al. Dulaglutide and Renal Outcomes in Type 2 Diabetes (REWIND). Lancet. 2019.
11. Mann JFE et al. Liraglutide and Renal Outcomes in Type 2 Diabetes (LEADER trial substudy). NEJM. 2017.
12. FDA Drug Label. Wegovy (semaglutide) Prescribing Information. Updated 2024.

Footer disclaimers

Platform Disclaimer. FormBlends provides educational content. Kidney disease management requires nephrology involvement and coordination with primary care or endocrinology. This article is not a substitute for personalized clinical evaluation by a qualified nephrologist.

Compounded Medication Notice. Compounded semaglutide is not FDA-approved and has not been studied in CKD trials. The renal indication applies specifically to brand-name Ozempic at the 1.0 mg dose used in FLOW. Compounded preparations are not interchangeable with brand-name products.

Results Disclaimer. FLOW described average outcomes across the trial population. Individual response varies by baseline eGFR, albuminuria, comorbidities, and adherence. The trial stop for efficacy may have produced effect size estimates that are larger than would be seen with full follow-up.

Trademark Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. SGLT2 inhibitor brand names belong to their respective manufacturers (Jardiance, Farxiga, Invokana, etc.). FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.